Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Oct;4(5):1085-95.

Bowen's disease - a review of newer treatment options

Thorsten Neubert  1 , Percy Lehmann
Affiliations

Bowen's disease - a review of newer treatment options

Thorsten Neubert et al. Ther Clin Risk Manag. 2008 Oct.

Abstract

Bowen's disease (squamous cell carcinoma in situ) has a 3%-5% risk to develop into invasive squamous cell carcinoma. Non-melanoma skin cancer is the most common cancer among Caucasians and its incidence has increased during the last decades dramatically. Multiple treatment options for Bowen's disease have been described and are established with advantages and disadvantages. Bowen's disease occurs more often in elderly patients (with a higher risk of comorbidities) and is frequently located on body sites with poor wound healing. Therefore there is need for non-invasive/non-destructive but effective treatment options.We would like to give an overview of established therapies and more detailed information about the newer treatment options for Bowen's disease with topical diclofenac, topical imiquimod and photodynamic therapy.

Keywords: Bowen’s disease; diclofenac; imiquimod; photodynamic therapy.

PubMed Disclaimer

References

    1. Ahmed I, Berth-Jones J, Charles-Holmes S, et al. Comparison of cryotherapy with curettage in the treatment of Bowen’s disease:a prospective study. Br J Dermatol. 2000;143:759–66. - PubMed
    1. Arlette JP. Treatment of Bowen’s disease and erythroplasia of Queyrat. Br J Dermatol. 2003;149:43–7. - PubMed
    1. Ball SB, Dawber RP. Treatment of cutaneous Bowen’s disease with particular emphasis on the problem of lower leg lesions. Australas J Dermatol. 1998;39:63–8. - PubMed
    1. Bargmann H, Hochmann J. Topical treatment of Bowen’s disease with 5-Fluorouracil. J Cutan Med Surg. 2003;7:101–5. - PubMed
    1. Bell HK, Rhodes LE. Bowen’s disease – a retrospective review of clinical management. Clin Exp Dermatol. 1999;24:338–9. - PubMed

LinkOut - more resources